UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/319,156	11/02/1999	GLAUCIA PARANHOS-BACCALA	103514	2490
25944 OLIFF & BERI	7590 05/13/200 RIDGE, PLC	EXAMINER		
P.O. BOX 3208	350	PARKIN, JEFFREY S		
ALEXANDRIA, VA 22320-4850			ART UNIT	PAPER NUMBER
			1648	
			MAIL DATE	DELIVERY MODE
			05/13/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
	09/319,156	PARANHOS-BACCALA ET AL.	
Office Action Summary	Examiner	Art Unit	
	Jeffrey S. Parkin	1648	
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tir will apply and will expire SIX (6) MONTHS from a, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on 29 S	action is non-final. nce except for formal matters, pro		
Disposition of Claims			
4) ☐ Claim(s) <u>1,7,9,14,15,26,60-64 and 66</u> is/are per 4a) Of the above claim(s) <u>26</u> is/are withdrawn f 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) <u>1,7,9,14,15,60-64 and 66</u> is/are reject 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	rom consideration.		
Application Papers			
9) ☐ The specification is objected to by the Examine 10) ☑ The drawing(s) filed on <u>07 November 2005</u> is/a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) ☐ The oath or declaration is objected to by the Ex	re: a)⊠ accepted or b)⊡ object drawing(s) be held in abeyance. Sec tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D: 5) Notice of Informal F 6) Other:	ate	

Detailed Office Action

Status of the Claims

As set forth in the advisory action dated 11 December, 2008, the finality of the final rejection dated 27 March, 2008, has been withdrawn. The amendment-after-final filed 29 September, 2008, has been entered. Claims 1, 7, 9, 14, 15, 26, 60-64, and 66 are pending in the instant application. Claim 26 stands withdrawn from further consideration by the examiner, pursuant to 37 C.F.R. § 1.142(b), as being drawn to a non-elected invention (see the restriction requirement mailed 16 February, 2001).

35 U.S.C. § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. § 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

The previous rejection of claims 1, 7, 14, 15, and 60-64 under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, is hereby withdrawn in response to applicants' amendment.

35 U.S.C. § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Written Description

The previous rejection of claims 1, 7, 9, 14, 15, and 60-64 under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, is hereby withdrawn in view of applicants' amendment.

35 U.S.C. § 102(b)

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The previous rejection of claims 1, 7, 14, 15, and 60 under 35 U.S.C. § 102(b) as being clearly anticipated by Boehringer Mannheim (1994), is hereby withdrawn in response to applicants' amendment.

35 U.S.C. § 119

Acknowledgment is hereby made of applicants' claim for foreign priority based on FR 97/08816 filed 07 July, 1997. It is noted, however, that applicants have **NOT** filed a certified copy **AND** English translation of this application as required by 35 U.S.C. § 119(b). Accordingly, the foreign priority claim has **NOT** been entered.

35 U.S.C. § 102(e)

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1, 7, 9, 14, 15, 60, 61, 63, and 66 are rejected under 35 U.S.C. § 102 (e) as being clearly anticipated by Perron *et al*. (2003, U.S. Patent No. 6,582,703 B2). Perron and associates provide isolated polynucleotides that are identical to SEQ ID NOS. 6, 9, 10, and 12 (see SEQ ID NOS.: 102, 105, 106, and 108,

1. The earliest effective filing date of U.S. Patent No. 6,582,703 B2 is 26 November, 1997.

respectively). Thus, this teaching meets all of the claimed limitations.

35 U.S.C. § 103(a)

The following is a quotation of 35 U.S.C. § 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 62 and 64 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Perron et al. (2003, U.S. Patent No. 6,582,703 B2). Claim 62 is directed toward isolated genomic DNA comprising SEQ ID NOS. 6, 9, or 12 and claim 64 is directed toward an expression vector comprising the claimed SEQ ID NOS. As set forth supra, Perron and associates provide isolated polynucleotides that are identical to SEQ ID NOS. 6, 9, and 12 (see SEQ ID NOS.: 102, 105, and 108, respectively). This teaching does not disclose isolated genomic DNA comprising these sequences or expression vectors comprising said sequences. However, it would have been prima facie obvious to one of ordinary skill in the art at the time of the invention to isolate the claimed retroviral sequences from a number of sources (e.g., genomic DNA comprising proviral copies of the retrovirus) to facilitate further genotypic/phenotypic

characterization of the virus. One of ordinary skill in the art would have also been motivated to place the claimed sequences in an expression vector to encode the corresponding protein. The protein would obviously be useful for the generation of a number of immunological, biochemical and diagnostic reagents.

Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Larry R. Helms, can be reached at (571) 272-0832. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Office (Office) requires most patent Trademark correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. For further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on

access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,

/Jeffrey S. Parkin/

Jeffrey S. Parkin, Ph.D. Primary Examiner, Art Unit 1648

10 May, 2009

Appendix A: Sequence Search Results for U.S. Serial No. 09/319,156

```
RESULT 1
US-08-979-847B-102
; Sequence 102, Application US/08979847B
; Patent No. 6582703
   GENERAL INFORMATION:
         APPLICANT: PERRON, HERVE
                    BESEME, FREDERIC
                    BEDIN, FREDERIC
                    PARANHOS-BACCALA, GLAUCIA
                    KOMURIAN-PRADEL, FLORENCE
                    JOLIVET-REYNAUD, COLETTE
                    MANDRAND, BERNARD
                    GARSON, JEREMY
                    TUKE, PHILIP
         TITLE OF INVENTION: VIRAL MATERIAL AND NUCLEOTIDE FRAGMENTS
                             ASSOCIATED WITH MULTIPLE SCLEROSIS, FOR
DIAGNOSTIC,
                            PROPHYLACTIC AND THERAPEUTIC PURPOSES
         NUMBER OF SEQUENCES: 210
         CORRESPONDENCE ADDRESS:
              ADDRESSEE: OLIFF & BERRIDGE, PLC
              STREET: P.O. BOX 19928
              CITY: ALEXANDRIA
              STATE: VA
              COUNTRY: USA
              ZIP: 22320
         COMPUTER READABLE FORM:
              MEDIUM TYPE: Floppy disk
              COMPUTER: IBM PC compatible
              OPERATING SYSTEM: PC-DOS/MS-DOS
              SOFTWARE: PatentIn Release #1.0, Version #1.30
         CURRENT APPLICATION DATA:
              APPLICATION NUMBER: US/08/979,847B
              FILING DATE: 26-No. 6582703-1997
              CLASSIFICATION:
         ATTORNEY/AGENT INFORMATION:
              NAME: BERRIDGE, WILLIAM P.
              REGISTRATION NUMBER: 30,024
              REFERENCE/DOCKET NUMBER: WPB 39046A
         TELECOMMUNICATION INFORMATION:
              TELEPHONE: 703-836-6400
              TELEFAX: 703-836-2787
   INFORMATION FOR SEQ ID NO: 102:
         SEQUENCE CHARACTERISTICS:
```

```
LENGTH: 635 base pairs
;
            TYPE: nucleic acid
;
            STRANDEDNESS: single
            TOPOLOGY: linear
       MOLECULE TYPE: cDNA
        SEOUENCE DESCRIPTION: SEO ID NO: 102:
US-08-979-847B-102
 Query Match
                       100.0%; Score 635; DB 4;
                                                Length 635;
 Best Local Similarity
                       100.0%;
                              Pred. No. 2e-203;
         635; Conservative 0; Mismatches
 Matches
                                             0;
                                                 Indels
                                                          0;
Gaps
       0;
        1 CCCTGTATCTTTAACCTCCTTGTTAAGTTTGTCTCTTCCAGAATCAAAACTGTAAAACTA 60
Qу
          1 CCCTGTATCTTTAACCTCCTTGTTAAGTTTGTCTCTCCAGAATCAAAACTGTAAAACTA 60
        61 CAAATTGTTCTTCAAATGGAGCACCAGATGGAGTCCATGACTAAGATCCACCGTGGACCC 120
Οv
          61 CAAATTGTTCTTCAAATGGAGCACCAGATGGAGTCCATGACTAAGATCCACCGTGGACCC 120
Db
       121 CTGGACCGGCCTGCTAGCCCATGCTCCGATGTTAATGACATTGAAGGCACCCCTCCCGAG 180
QУ
          121 CTGGACCGCCTGCTAGCCCATGCTCCGATGTTAATGACATTGAAGGCACCCCTCCCGAG 180
Db
       181 GAAATCTCAACTGCACAACCCCTACTATGCCCCAATTCAGCGGGAAGCAGTTAGAGCGGT 240
QУ
          181 GAAATCTCAACTGCACAACCCCTACTATGCCCCAATTCAGCGGGAAGCAGTTAGAGCGGT 240
Db
       241 CATCAGCCAACCTCCCCAACAGCACTTGGGTTTTCCTGTTGAGAGGGGGGGACTGAGAGAC 300
QУ
          241 CATCAGCCAACCTCCCCAACAGCACTTGGGTTTTCCTGTTGAGAGGGGGGGACTGAGAGAC 300
Db
       301 AGGACTAGCTGGATTTCCTAGGCCAACGAAGAATCCCTAAGCCTAGCTGGGAAGGTGACT 360
Qy
          301 AGGACTAGCTGGATTTCCTAGGCCAACGAAGAATCCCTAAGCCTAGCTGGGAAGGTGACT 360
Db
       361 GCATCCACCTCTAAACATGGGGCTTGCAACTTAGCTCACACCCGACCAATCAGAGAGCTC 420
QУ
          361 GCATCCACCTCTAAACATGGGGCTTGCAACTTAGCTCACACCCGACCAATCAGAGAGCTC 420
Db
       421 ACTAAAATGCTAATTAGGCAAAAATAGGAGGTAAAGAAATAGCCAATCATCTATTGCCTG 480
QУ
          421 ACTAAAATGCTAATTAGGCAAAAATAGGAGGTAAAGAAATAGCCAATCATCTATTGCCTG 480
       481 AGAGCACAGCGGGAGGGACAAGGATCGGGATATAAACCCAGGCATTCGAGCCGGCAACGG 540
QУ
          481 AGAGCACAGCGGGAGGACAAGGATCGGGATATAAACCCAGGCATTCGAGCCGGCAACGG 540
Db
       541 CAACCCCTTTGGGTCCCCTCCTTTGTATGGGCGCTCTGTTTTCACTCTATTTCACTCT 600
0.7
          541 CAACCCCTTTGGGTCCCCTCCTTTGTATGGGCGCTCTGTTTTCACTCTATTTCACTCT 600
Db
       601 ATTAAATCTTGCAACTGAAAAAAAAAAAAAAAAAAA 635
Qv
          601 ATTAAATCTTGCAACTGAAAAAAAAAAAAAAAAAAA 635
Db
```

```
RESULT 1
US-08-979-847B-105
; Sequence 105, Application US/08979847B
; Patent No. 6582703
   GENERAL INFORMATION:
    APPLICANT: PERRON, HERVE
                    BESEME, FREDERIC
                    BEDIN, FREDERIC
                    PARANHOS-BACCALA, GLAUCIA
                    KOMURIAN-PRADEL, FLORENCE
                    JOLIVET-REYNAUD, COLETTE
                    MANDRAND, BERNARD
                    GARSON, JEREMY
                    TUKE, PHILIP
         TITLE OF INVENTION: VIRAL MATERIAL AND NUCLEOTIDE FRAGMENTS
                             ASSOCIATED WITH MULTIPLE SCLEROSIS, FOR
DIAGNOSTIC, PROPHYLACTIC AND
                             THERAPEUTIC PURPOSES
        NUMBER OF SEQUENCES: 210
         CORRESPONDENCE ADDRESS:
              ADDRESSEE: OLIFF & BERRIDGE, PLC
              STREET: P.O. BOX 19928
              CITY: ALEXANDRIA
              STATE: VA
              COUNTRY: USA
              ZIP: 22320
         COMPUTER READABLE FORM:
              MEDIUM TYPE: Floppy disk
              COMPUTER: IBM PC compatible
              OPERATING SYSTEM: PC-DOS/MS-DOS
              SOFTWARE: PatentIn Release #1.0, Version #1.30
         CURRENT APPLICATION DATA:
              APPLICATION NUMBER: US/08/979,847B
              FILING DATE: 26-No. 6582703-1997
              CLASSIFICATION:
        ATTORNEY/AGENT INFORMATION:
              NAME: BERRIDGE, WILLIAM P.
              REGISTRATION NUMBER: 30,024
              REFERENCE/DOCKET NUMBER: WPB 39046A
         TELECOMMUNICATION INFORMATION:
              TELEPHONE: 703-836-6400
              TELEFAX: 703-836-2787
    INFORMATION FOR SEQ ID NO: 105:
         SEQUENCE CHARACTERISTICS:
              LENGTH: 1481 base pairs
              TYPE: nucleic acid
              STRANDEDNESS: single
```

```
TOPOLOGY: linear
;
       MOLECULE TYPE: cDNA
;
       SEQUENCE DESCRIPTION: SEQ ID NO: 105:
US-08-979-847B-105
 Query Match
                       100.0%; Score 1481; DB 4; Length 1481;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1481; Conservative
                          0; Mismatches
                                             0;
                                                Indels
                                                         0;
Gaps
      0;
        1 ATGGCCCTCCCTTATCATACTTTTCTCTTTACTGTTCTCTTACCCCCTTTCGCTCTCACT 60
Qу
          1 ATGGCCCTCCCTTATCATACTTTTCTCTTTACTGTTCTCTTACCCCCTTTCGCTCTCACT 60
Db
        61 GCACCCCTCCATGCTGCTGTACAACCAGTAGCTCCCCTTACCAAGAGTTTCTATGAAGA 120
QУ
          61 GCACCCCTCCATGCTGCTGTACAACCAGTAGCTCCCCTTACCAAGAGTTTCTATGAAGA 120
Db
QУ
       121 ACGCGGCTTCCTGGAAATATTGATGCCCCATCATATAGGAGTTTATCTAAGGGAAACTCC 180
          121 ACGCGGCTTCCTGGAAATATTGATGCCCCATCATATAGGAGTTTATCTAAGGGAAACTCC 180
Db
       181 ACCTTCACTGCCCACACCCATATGCCCCGCAACTGCTATAACTCTGCCACTCTTTGCATG 240
QУ
          181 ACCTTCACTGCCCACACCCATATGCCCCGCAACTGCTATAACTCTGCCACTCTTTGCATG 240
Db
       241 CATGCAAATACTCATTATTGGACAGGGAAAATGATTAATCCTAGTTGTCCTGGAGGACTT 300
QУ
          241 CATGCAAATACTCATTATTGGACAGGGAAAATGATTAATCCTAGTTGTCCTGGAGGACTT 300
Db
       301 GGAGCCACTGTCTGTTGGACTTACTTCACCCATACCAGTATGTCTGATGGGGGTTGGAATT 360
Qv
          Db
       301 GGAGCCACTGTCTGTAGGACTTACTTCACCCATACCAGTATGTCTGATGGGGGTTGGAATT 360
       361 CAAGGTCAGGCAAGAGAAAACAAGTAAAGGAAGCAATCTCCCAACTGACCCGGGGACAT 420
ΟV
          361 CAAGGTCAGGCAAGAGAAAACAAGTAAAGGAAGCAATCTCCCAACTGACCCGGGGACAT 420
Db
       421 AGCACCCCTAGCCCCTACAAAGGACTAGTTCTCTCAAAACTACATGAAACCCTCCGTACC 480
Ov
          421 AGCACCCCTAGCCCCTACAAAGGACTAGTTCTCTCAAAACTACATGAAACCCTCCGTACC 480
Db
       481 CATACTCGCCTGGTGAGCCTATTTAATACCACCCTCACTCGGCTCCATGAGGTCTCAGCC 540
QУ
          481 CATACTCGCCTGGTGAGCCTATTTAATACCACCCTCACTCGGCTCCATGAGGTCTCAGCC 540
Db
       541 CAAAACCCTACTAACTGTTGGATGTGCCTCCCCTGCACTTCAGGCCATACATTTCAATC 600
0v
          Db
       541 CAAAACCCTACTAACTGTTGGATGTCCCCCCTGCACTTCAGGCCATACATTTCAATC 600
       601 CCTGTTCCTGAACAATGGAACAACTTCAGCACAGAAATAAACACCACTTCCGTTTTAGTA 660
QУ
          601 CCTGTTCCTGAACAATGGAACAACTTCAGCACAGAAATAAACACCACTTCCGTTTTAGTA 660
Db
       661 GGACCTCTTGTTTCCAATCTGGAAATAACCCATACCTCAAACCTCACCTGTGTAAAATTT 720
Qу
          661 GGACCTCTTGTTTCCAATCTGGAAATAACCCATACCTCAAACCTCACCTGTGTAAAATTT 720
Db
```

Qу	721	${\tt AGCAATACTATAGACAACCAGCTCCCAATGCATCAGGTGGGTAACACCTCCCACACGA}$	780
Db	721	AGCAATACTATAGACAACCAGCTCCCAATGCATCAGGTGGGTAACACCTCCCACACGA	780
QУ	781	$\tt ATAGTCTGCCTACCCTCAGGAATATTTTTTTGTCTGTGGTACCTCAGCCTATCATTGTTTG$	840
Db	781	ATAGTCTGCCTACCCTCAGGAATATTTTTGTCTGTGGTACCTCAGCCTATCATTGTTTG	840
Qу	841	AATGGCTCTTCAGAATCTATGTGCTTCCTCTCATTCTTAGTGCCCCCTATGACCATCTAC	900
Db	841	AATGGCTCTTCAGAATCTATGTGCTTCCTCTATTCTTAGTGCCCCCTATGACCATCTAC	900
QУ	901	ACTGAACAAGATTTATACAATCATGTCGTACCTAAGCCCCACAACAAAAGAGTACCCATT	960
Db	901	ACTGAACAAGATTTATACAATCATGTCGTACCTAAGCCCCACAACAAAAGAGTACCCATT	960
QУ	961	CTTCCTTTTGTTATCAGAGCAGGAGTGCTAGGCAGACTAGGTACTGGCAGTATC	1020
Db	961	CTTCCTTTTGTTATCAGAGCAGGAGTGCTAGGCAGACTAGGTACTGGCATTGGCAGTATC	1020
QУ	1021	ACAACCTCTACTCAGTTCTACTACAAACTATCTCAAGAAATAAAT	1080
Db	1021	ACAACCTCTACTCAGTTCTACTACAAACTATCTCAAGAAATAAAT	1080
QУ	1081	GTCACTGACTCCCTGGTCACCTTGCAAGATCAACTTAACTCCCTAGCAGCAGTAGTCCTT	1140
Db	1081	GTCACTGACTCCCTGGTCACCTTGCAAGATCAACTTAACTCCCTAGCAGCAGTAGTCCTT	1140
Qу	1141	CAAAATCGAAGAGCTTTAGACTTGCTAACCGCCAAAAGAGGGGGGAACCTGTTTATTTTTA	1200
Db	1141	CAAAATCGAAGAGCTTTAGACTTGCTAACCGCCAAAAGAGGGGGAACCTGTTTATTTTTA	1200
QУ	1201	GGAGAAGAACGCTGTTATTATGTTAATCAATCCAGAATTGTCACTGAGAAAGTTAAAGAA	1260
Db	1201	GGAGAAGAACGCTGTTATTATGTTAATCAATCCAGAATTGTCACTGAGAAAGTTAAAGAA	1260
QУ	1261	$\tt ATTCGAGATCGAATACAATGTAGAGCAGAGGAGGTTCAAAACACCGAACGCTGGGGCCTC$	1320
Db	1261	ATTCGAGATCGAATACAATGTAGAGCAGAGGAGCTTCAAAACACCGAACGCTGGGGCCTC	1320
QУ	1321	CTCAGCCAATGGATGCCCTGGGTTCTCCCCTTCTTAGGACCTCTAGCAGCTCTAATATTG	1380
Db	1321	CTCAGCCAATGGATGCCCTGGGTTCTCCCCTTCTTAGGACCTCTAGCAGCTCTAATATTG	1380
QУ	1381		1440
Db	1381	TTACTCCTCTTTGGACCCTGTATCTTTAACCTCCTTGTTAAGTTTGTCTCTTCCAGAATT	1440
QУ	1441	GAAGCTGTAAAGCTACAGATGGTCTTACAAATGGAACCCCA 1481	
Dh	1441		

```
RESULT 1
US-08-979-847B-106
; Sequence 106, Application US/08979847B
; Patent No. 6582703
   GENERAL INFORMATION:
    APPLICANT: PERRON, HERVE
                    BESEME, FREDERIC
                    BEDIN, FREDERIC
                    PARANHOS-BACCALA, GLAUCIA
                    KOMURIAN-PRADEL, FLORENCE
                    JOLIVET-REYNAUD, COLETTE
                    MANDRAND, BERNARD
                    GARSON, JEREMY
                    TUKE, PHILIP
         TITLE OF INVENTION: VIRAL MATERIAL AND NUCLEOTIDE FRAGMENTS
                             ASSOCIATED WITH MULTIPLE SCLEROSIS, FOR
DIAGNOSTIC, PROPHYLACTIC AND
                             THERAPEUTIC PURPOSES
        NUMBER OF SEQUENCES: 210
         CORRESPONDENCE ADDRESS:
              ADDRESSEE: OLIFF & BERRIDGE, PLC
              STREET: P.O. BOX 19928
              CITY: ALEXANDRIA
              STATE: VA
              COUNTRY: USA
              ZIP: 22320
         COMPUTER READABLE FORM:
              MEDIUM TYPE: Floppy disk
              COMPUTER: IBM PC compatible
              OPERATING SYSTEM: PC-DOS/MS-DOS
              SOFTWARE: PatentIn Release #1.0, Version #1.30
         CURRENT APPLICATION DATA:
              APPLICATION NUMBER: US/08/979,847B
              FILING DATE: 26-No. 6582703-1997
              CLASSIFICATION:
        ATTORNEY/AGENT INFORMATION:
              NAME: BERRIDGE, WILLIAM P.
              REGISTRATION NUMBER: 30,024
              REFERENCE/DOCKET NUMBER: WPB 39046A
         TELECOMMUNICATION INFORMATION:
              TELEPHONE: 703-836-6400
              TELEFAX: 703-836-2787
    INFORMATION FOR SEQ ID NO: 106:
         SEQUENCE CHARACTERISTICS:
              LENGTH: 493 amino acids
              TYPE: amino acid
              STRANDEDNESS: single
```

```
TOPOLOGY: linear
;
       MOLECULE TYPE: peptide
       SEQUENCE DESCRIPTION: SEQ ID NO: 106:
US-08-979-847B-106
 Query Match
                       99.9%; Score 2632; DB 4; Length 493;
 Best Local Similarity 100.0%; Pred. No. 2.8e-262;
 Matches 493; Conservative 0; Mismatches 0; Indels
                                                         0;
Gaps
        1 MALPYHTFLFTVLLPPFALTAPPPCCCTTSSSPYQEFLXRTRLPGNIDAPSYRSLSKGNS 60
Qу
          Db
        1 MALPYHTFLFTVLLPPFALTAPPPCCCTTSSSPYQEFLXRTRLPGNIDAPSYRSLSKGNS 60
        61 TFTAHTHMPRNCYNSATLCMHANTHYWTGKMINPSCPGGLGATVCWTYFTHTSMSDGGGI 120
Qv
          61 TFTAHTHMPRNCYNSATLCMHANTHYWTGKMINPSCPGGLGATVCWTYFTHTSMSDGGGI 120
Db
       121 QGQAREKQVKEAISQLTRGHSTPSPYKGLVLSKLHETLRTHTRLVSLFNTTLTRLHEVSA 180
QУ
          Db
       121 OGOAREKOVKEAISOLTRGHSTPSPYKGLVLSKLHETLRTHTRLVSLFNTTLTRLHEVSA 180
       181 QNPTNCWMCLPLHFRPYISIPVPEQWNNFSTEINTTSVLVGPLVSNLEITHTSNLTCVKF 240
Qy
          181 QNPTNCWMCLPLHFRPYISIPVPEQWNNFSTEINTTSVLVGPLVSNLEITHTSNLTCVKF 240
Db
       241 SNTIDTTSSQCIRWVTPPTRIVCLPSGIFFVCGTSAYHCLNGSSESMCFLSFLVPPMTIY 300
QУ
          241 SNTIDTTSSOCIRWVTPPTRIVCLPSGIFFVCGTSAYHCLNGSSESMCFLSFLVPPMTIY 300
Db
       301 TEQDLYNHVVPKPHNKRVPILPFVIRAGVLGRLGTGIGSITTSTQFYYKLSQEINGDMEQ 360
QУ
          301 TEQDLYNHVVPKPHNKRVPILPFVIRAGVLGRLGTGIGSITTSTQFYYKLSQEINGDMEQ 360
Db
       361 VTDSLVTLQDQLNSLAAVVLQNRRALDLLTAKRGGTCLFLGEERCYYVNQSRIVTEKVKE 420
QУ
          361 VTDSLVTLQDQLNSLAAVVLQNRRALDLLTAKRGGTCLFLGEERCYYVNQSRIVTEKVKE 420
Db
       421 IRDRIQCRAEELQNTERWGLLSQWMPWVLPFLGPLAALILLLLFGPCIFNLLVKFVSSRI 480
QУ
          421 IRDRIOCRAEELONTERWGLLSOWMPWVLPFLGPLAALILLLLFGPCIFNLLVKFVSSRI 480
Db
       481 EAVKLQMVLQMEP 493
Qy
          481 EAVKLQMVLQMEP 493
Db
```

```
RESULT 1
US-08-979-847B-108
; Sequence 108, Application US/08979847B
; Patent No. 6582703
    GENERAL INFORMATION:
    APPLICANT: PERRON, HERVE
                    BESEME, FREDERIC
                    BEDIN, FREDERIC
                    PARANHOS-BACCALA, GLAUCIA
                    KOMURIAN-PRADEL, FLORENCE
                    JOLIVET-REYNAUD, COLETTE
                    MANDRAND, BERNARD
                    GARSON, JEREMY
                    TUKE, PHILIP
         TITLE OF INVENTION: VIRAL MATERIAL AND NUCLEOTIDE FRAGMENTS
                             ASSOCIATED WITH MULTIPLE SCLEROSIS, FOR
DIAGNOSTIC, PROPHYLACTIC AND
                             THERAPEUTIC PURPOSES
         NUMBER OF SEQUENCES: 210
         CORRESPONDENCE ADDRESS:
              ADDRESSEE: OLIFF & BERRIDGE, PLC
              STREET: P.O. BOX 19928
              CITY: ALEXANDRIA
              STATE: VA
              COUNTRY: USA
              ZIP: 22320
         COMPUTER READABLE FORM:
              MEDIUM TYPE: Floppy disk
              COMPUTER: IBM PC compatible
              OPERATING SYSTEM: PC-DOS/MS-DOS
              SOFTWARE: PatentIn Release #1.0, Version #1.30
         CURRENT APPLICATION DATA:
              APPLICATION NUMBER: US/08/979,847B
              FILING DATE: 26-No. 6582703-1997
              CLASSIFICATION:
        ATTORNEY/AGENT INFORMATION:
              NAME: BERRIDGE, WILLIAM P.
              REGISTRATION NUMBER: 30,024
              REFERENCE/DOCKET NUMBER: WPB 39046A
         TELECOMMUNICATION INFORMATION:
              TELEPHONE: 703-836-6400
              TELEFAX: 703-836-2787
    INFORMATION FOR SEQ ID NO: 108:
         SEQUENCE CHARACTERISTICS:
              LENGTH: 1329 base pairs
              TYPE: nucleic acid
              STRANDEDNESS: single
```

```
TOPOLOGY: linear
;
       MOLECULE TYPE: cDNA
;
       SEQUENCE DESCRIPTION: SEQ ID NO: 108:
US-08-979-847B-108
 Query Match
                       99.8%;
                              Score 1326; DB 4;
                                               Length 1329;
 Best Local Similarity
                       100.0%; Pred. No. 0;
 Matches 1329; Conservative
                           0; Mismatches
                                                         0;
                                             0;
                                                Indels
Gaps
        1 TCAAAATCGAAGAGCTTTAGACTTGCTAACCGCCAAAAGAGGGGGAACCTGTTTATTTT 60
QУ
          1 TCAAAATCGAAGAGCTTTAGACTTGCTAACCGCCAAAAGAGGGGGGAACCTGTTTATTTTT 60
Db
        61 AGGGGAAGAATGCTGTTAGTATGTTAATCAATCTGGAATCATTACTGAGAAAGTTAAAGA 120
QУ
          61 AGGGGAAGAATGCTGTTAGTATGTTAATCAATCTGGAATCATTACTGAGAAAGTTAAAGA 120
Db
       121 AATTTGAGATCGAATATAATGTAGAGCAGAGGACCTTCAAAACACTGCACCCTGGGGCCT 180
QУ
          Db
       121 AATTTGAGATCGAATATAATGTAGAGCAGAGGACCTTCAAAACACTGCACCCTGGGGCCT 180
       181 CCTCAGCCAATGGATGCCCTGGACTCTCCCCTTCTTAGGACCTCTAGCAGCTATAATATT 240
Qy
          181 CCTCAGCCAATGGATGCCCTGGACTCTCCCCTTCTTAGGACCTCTAGCAGCTATAATATT 240
Db
       241 TTTACTCCTCTTTGGACCCTGTATCTTCAACTTCCTTGTTAAGTTTGTCTCTTCCAGAAT 300
QУ
          241 TTTACTCCTCTTTGGACCCTGTATCTTCAACTTCCTTGTTAAGTTTGTCTCTTCCAGAAT 300
Db
       301 TGAAGCTGTAAAGCTACAAATAGTTCTTCAAATGGAACCCCAGATGCAGTCCATGACTAA 360
QУ
          301 TGAAGCTGTAAAGCTACAAATAGTTCTTCAAATGGAACCCCAGATGCAGTCCATGACTAA 360
Dh
       361 AATCTACCGTGGACCCTGGACCGCCTGCTAGACTATGCTCTGATGTTAATGACATTGA 420
Qv
          361 AATCTACCGTGGACCCTGGACCGCCTGCTAGACTATGCTCTGATGTTAATGACATTGA 420
Db
       421 AGTCACCCCTCCGAGGAAATCTCAACTGCACAACCCCTACTACACTCCAATTCAGTAGG 480
QУ
          421 AGTCACCCCTCCGAGGAAATCTCAACTGCACAACCCCTACTACACTCCAATTCAGTAGG 480
Db
       481 AAGCAGTTAGAGCAGTTGTCAGCCAACCTCCCCAACAGTACTTGGGTTTTCCTGTTGAGA 540
Qv
          481 AAGCAGTTAGAGCAGTTGTCAGCCAACCTCCCCAACAGTACTTGGGTTTTCCTGTTGAGA 540
Db
       541 GGGTGGACTGAGAGACAGGACTAGCTGGATTTCCTAGGCTGACTAAGAATCCCNAAGCCT 600
Qv
          541 GGGTGGACTGAGAGACAGGACTAGCTGGATTTCCTAGGCTGACTAAGAATCCCNAAGCCT 600
Db
       601 ANCTGGGAAGGTGACCGCATCCATCTTTAAACATGGGGCTTGCAACTTAGCTCACACCCG 660
ΟV
          Db
       601 ANCTGGGAAGGTGACCGCATCCATCTTTAAACATGGGGCTTGCAACTTAGCTCACACCCG 660
       661 ACCAATCAGAGAGCTCACTAAAATGCTAATCAGGCAAAAACAGGAGGTAAAGCAATAGCC 720
QУ
          661 ACCAATCAGAGAGCTCACTAAAATGCTAATCAGGCAAAAACAGGAGGTAAAGCAATAGCC 720
Db
```

QУ	721	AATCATCTATTGCCTGAGAGCACAGCGGGAAGGACAAGGATTGGGATATAAACTCAGGCA	780
Db	721	AATCATCTATTGCCTGAGAGCACAGCGGGAAGGACAAGGATTGGGATATAAACTCAGGCA	780
QУ	781	${\tt TTCAAGCCAGCAACAGCAACCCCTTTGGGTCCCCTCCCATTGTATGGGAGCTCTGTTTT}$	840
Db	781	TTCAAGCCAGCAACAGCAACCCCCTTTGGGTCCCCTCCCATTGTATGGGAGCTCTGTTTT	840
Qу	841	${\tt CACTCTATTTCACTCTATTAAATCATGCAACTGCACTCTTCTGGTCCGTGTTTTTTATGG}$	900
Db	841		900
Qу	901	$\tt CTCAAGCTGAGCTTTTGTTCGCCATCCACCACTGCTGTTTGCCACCGTCACAGACCCGCT$	960
Db	901	CTCAAGCTGAGCTTTTGTTCGCCATCCACCACTGCTGTTTGCCACCGTCACAGACCCGCT	960
QУ	961	${\tt GCTGACTTCCATCCCTTTGGATCCAGCAGAGTGTCCACTGTGCTCCTGATCCAGCGAGGT}$	1020
Db	961		1020
QУ	1021	${\tt ACCCATTGCCACTCCCGATCAGGCTAAAGGCTTGCCATTGTTCCTGCATGGCTAAGTGCC}$	1080
Db	1021	ACCCATTGCCACTCCCGATCAGGCTAAAGGCTTGCCATTGTTCCTGCATGGCTAAGTGCC	1080
QУ	1081	TGGGTTTGTCCTAATAGAACTGAACACTGGTCACTGGGTTCCATGGTTCTCTCCATGAC	1140
Db	1081	TGGGTTTGTCCTAATAGAACTGAACACTGGTCACTGGTTCCATGGTTCTCTTCCATGAC	1140
QУ	1141	$\tt CCACGGCTTCTAATAGAGCTATAACACTCACCGCATGGCCCAAGATTCCATTCCTTGGTA$	1200
Db	1141	CCACGGCTTCTAATAGAGCTATAACACTCACCGCATGGCCCAAGATTCCATTCCTTGGTA	1200
Qу	1201	${\tt TCTGTGAGGCCAAGAACCCCAGGTCAGAGAANGTGAGGCTTGCCACCATTTGGGAAGTGG}$	1260
Db	1201	TCTGTGAGGCCAAGAACCCCAGGTCAGAGAANGTGAGGCTTGCCACCATTTGGGAAGTGG	1260
Qу	1261	CCCACTGCCATTTTGGTAGCGGCCCACCACCATCTTGGGAGCTGTGGGAGCAAGGATCCC	1320
Db	1261	CCCACTGCCATTTTGGTAGCGGCCCACCACCATCTTGGGAGCTGTGGGAGCAAGGATCCC	1320
QУ	1321	CCAGTAACA 1329	
Db	1321	CCAGTAACA 1329	